Dr. Peter Neumann will moderate an issue panel at the ISPOR 21st Annual International Meeting this Monday, May 23rd, entitled "What's next for value frameworks for prescription drugs?" The panel will discuss key challenges faced by the nascent value-assessment frameworks that have arisen in recent years, including:
- What dimensions of value should be accounted for?
- How should the dimensions be weighted?
- What roles should formal cost-effectiveness analysis and budget impact analysis play and how should they be measured?
- How should the frameworks be used and by whom?
In addition to Dr. Neumann, the panel will include: Dr. Lowell Schipper of Harvard Medical School; Dr. Dan Ollendorf of the Institute for Clinical and Economic Review; and Dr. Josh Ofman of Amgen.Read more here.
Event 5/22/16ISPOR 2016: Goldman to moderate panel on pharmaceutical pricing
Dana Goldman will moderate a May 24th panel at the 21st Annual International Meeting of ISPOR titled "Pharmaceutical pricing in the United States: Are we balancing innovation and affordability?"READ MORE